<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Routine monitoring of children and adolescents with type 2 diabetes for chronic complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Routine monitoring of children and adolescents with type 2 diabetes for chronic complications</h1>
<div class="graphic"><div class="figure"><div class="ttl">Routine monitoring of children and adolescents with type 2 diabetes for chronic complications</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Evaluation</td> <td class="subtitle1">Screening approach</td> <td class="subtitle1">Abnormal result</td> <td class="subtitle1">Usual treatment</td> </tr> <tr> <td rowspan="2"><strong>Hypertension</strong></td> <td rowspan="2">Measure BP at each routine visit, with additional visits as needed if BP is elevated.</td> <td>Adolescents ≥13 <span class="nowrap_whitespace">years:*<sup>[1,2]</sup></span> <ul class="decimal_heading"> <li>Elevated BP – SBP 120 to 129 with DBP &lt;80</li> </ul> (Measured on 3 occasions) </td> <td> <ul> <li>Nonpharmacologic intervention (diet and exercise, with weight reduction if appropriate)</li> <li>Initiate pharmacologic intervention (ACE inhibitor or ARB)<sup>¶</sup> if BP remains in this range despite nonpharmacologic intervention for 3 to 6 months</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li><span class="nowrap_whitespace">Hypertension<sup>[1]</sup></span> – SBP ≥130 or DBP ≥80</li> </ul> (Measured on 3 occasions) </td> <td> <ul> <li>Continue and intensify nonpharmacologic intervention, <strong>and</strong></li> <li>Initiate pharmacologic intervention (ACE inhibitor or <span class="nowrap_whitespace">ARB)<sup>¶</sup><sup>[3]</sup></span></li> </ul> </td> </tr> <tr> <td rowspan="3"><strong>Dyslipidemia</strong></td> <td rowspan="3">Lipid panel at diagnosis of diabetes, once glycemic control is achieved. If sample was nonfasting (random) and results are indeterminate, confirm with a fasting lipid panel. Repeat annually.</td> <td>LDL ≥100 to 130 mg/dL (2.59 to 3.36 mmol/L)</td> <td> <ul> <li>Nonpharmacologic intervention – Optimize glycemic control; exercise and diet to limit dietary cholesterol (≤200 mg/day) and saturated fat (≤7% of total calories) and aim to attain and maintain healthy body weight</li> <li>Aim for LDL ≤100 mg/dL</li> </ul> </td> </tr> <tr> <td>LDL ≥130 mg/dL (≥3.36 mmol/L)</td> <td> <ul> <li>Pharmacologic intervention (statin) for children ≥10 years if nonpharmacologic intervention is not successful after 6 months, and after reproductive counseling</li> <li>Aim for LDL ≤100 mg/dL</li> </ul> </td> </tr> <tr> <td>TG ≥150</td> <td> <ul> <li>Optimize glycemic control and weight reduction</li> <li>In the rare patient with fasting TG ≥400 mg/dL (4.5 mmol/L), treat with fibric acid</li> </ul> </td> </tr> <tr> <td><strong>Nephropathy</strong></td> <td>UACR (spot specimen). If abnormal, repeat on at least 2 occasions during the next 3 to 6 months. Repeat screening annually.</td> <td>UACR ≥30 mg albumin/g creatinine<sup>Δ</sup></td> <td> <ul> <li>Treat (ACE inhibitor or ARB)<sup>¶</sup> if BP is elevated, targeting normal BP</li> <li>Treat (ACE inhibitor or ARB)<sup>¶</sup> if UACR is ≥300 mg albumin/g creatinine, regardless of BP</li> <li>Treatment may be appropriate for patients with normal BP and moderately elevated UACR (30 to 300 mg albumin/g creatinine) that is persistent and increasing</li> </ul> </td> </tr> <tr> <td><strong>Retinopathy</strong></td> <td>Dilated eye examination or retinal imaging. Repeat annually or as advised by eye care professional.</td> <td>Nonproliferative, preproliferative, or proliferative retinopathy</td> <td> <ul> <li>Optimizing glycemic control may reverse nonproliferative retinopathy</li> <li>Laser therapy or intravitreous injections for more advanced disease</li> </ul> </td> </tr> <tr> <td><strong>Neuropathy</strong></td> <td>Foot examination (pulses and ankle reflex); sensory testing for vibration (tuning fork) and sensation (10 g monofilament). Repeat annually.</td> <td>Any abnormalities</td> <td> <ul> <li>Refer to neurologist for further evaluation</li> <li>Optimize glycemic control</li> </ul> </td> </tr> <tr> <td><strong>Psychosocial assessment</strong></td> <td>Screen for depression, eating disorders, family conflict, risk-taking behaviors, or other psychosocial dysfunction. Repeat at each routine visit or as needed.</td> <td>Clinical symptoms of depression, eating disorder, or psychosocial dysfunction</td> <td> <ul> <li>Refer to mental health professional</li> <li>Preconception counseling for girls of childbearing potential</li> </ul> </td> </tr> <tr> <td><strong>Smoking</strong></td> <td>Ask about use or experimentation with tobacco products including vaping (e-cigarettes). Provide anticipatory guidance to avoid smoking and vaping. Repeat at each routine visit.</td> <td>History of smoking or vaping</td> <td> <ul> <li>Advise that smoking increases the vascular and kidney complications of diabetes in addition to other health effects, and discourage all smoking and vaping</li> <li>For youth who smoke or vape, provide counseling and/or referral for cessation assistance</li> <li>Refer to UpToDate content on smoking and vaping cessation in adolescents</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table reflects recommendations for routine monitoring of children and adolescents with type 2 diabetes, as outlined by the American Diabetes <span class="nowrap_whitespace">Association<sup>[1]</sup>.</span></div><div class="graphic_footnotes"><p>BP: blood pressure; 
         SBP: systolic blood pressure; 
         DBP: diastolic blood pressure; 
         ACE: angiotensin-converting enzyme; 
         ARB: angiotensin receptor blocker; 
         LDL: low-density lipoprotein; 
         TG: triglycerides; 
         UACR: urine albumin-to-creatinine ratio.</p>
<p>* For children &lt;13 years, elevated BP (prehypertension) is defined as BP 90<sup>th</sup> to 95<sup>th</sup> percentile and hypertension BP ≥95<sup>th</sup> percentile. Refer to UpToDate topic and table for American Academy of Pediatrics definitions for pediatric BP categories.</p>
<p>¶ ACE inhibitors (eg, lisinopril or enalapril) and ARBs have teratogenic potential, so appropriate reproductive counseling should be given to young females. Aim for BP consistently &lt;120/80 mmHg (or &lt;90<sup>th</sup> percentile for children &lt;13 years).</p>
    
    Δ Transient albuminuria is common in children. Abnormal results should be confirmed on at least 2 occasions, ruling out orthostatic albuminuria with a first morning sample, or with a 24-hour urine collection.</div><div class="graphic_reference">References:
    <ol>
<li>American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S208.</li>
<li>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140:e20171904.</li>
<li>Donaghue KC, Marcovecchio ML, Wadwa RP, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes 2018; 19:262.</li>
</ol></div><div id="graphicVersion">Graphic 129761 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
